Recent advances in targeted strategies for triple-negative breast cancer

[1]  L. Shang,et al.  The role of organoids in cancer research , 2023, Experimental Hematology & Oncology.

[2]  K. Saravanamurali,et al.  Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment , 2023, Medical Oncology.

[3]  Xin Hu,et al.  FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer. , 2023, Journal of Clinical Oncology.

[4]  M. Goetz,et al.  Advances in systemic therapies for triple negative breast cancer , 2023, BMJ.

[5]  Shenglin Luo,et al.  A Mitochondria‐Targeted Ferroptosis Inducer Activated by Glutathione‐Responsive Imaging and Depletion for Triple Negative Breast Cancer Theranostics , 2023, Advanced healthcare materials.

[6]  M. Moses,et al.  A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo , 2023, Science advances.

[7]  Xinrun Wang,et al.  Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Qiang Wang,et al.  Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  N. Zhang,et al.  Targeting Trop-2 in cancer: Recent research progress and clinical application. , 2023, Biochimica et biophysica acta. Reviews on cancer.

[10]  T. Haque,et al.  Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer , 2023, British Journal of Cancer.

[11]  Khaled M. Elokely,et al.  Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer , 2023, International journal of biological sciences.

[12]  M. Zhou,et al.  New frontiers in immune checkpoint B7-H3 (CD276) research and drug development , 2023, Molecular Cancer.

[13]  H. Ditzel,et al.  Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer , 2023, International journal of molecular sciences.

[14]  K. Nephew,et al.  Glutamine metabolism in breast cancer and possible therapeutic targets. , 2023, Biochemical pharmacology.

[15]  H. Kumar,et al.  A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer , 2023, Journal of advanced research.

[16]  Lingfeng Zhu,et al.  Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment , 2023, Experimental Hematology & Oncology.

[17]  H. Xiong,et al.  Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer , 2023, Frontiers in Oncology.

[18]  Xun Yuan,et al.  Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  Chuang Chen,et al.  Breast cancer heterogeneity and its implication in personalized precision therapy , 2023, Experimental Hematology & Oncology.

[20]  Li Jiang,et al.  The Achilles heel of TNBCs: Ferroptosis heterogeneity. , 2023, Cell metabolism.

[21]  C. Omarini,et al.  Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges , 2023, Biomedicines.

[22]  Binyuan Jiang,et al.  PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds , 2023, Biomolecules.

[23]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[24]  L. Häberle,et al.  Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). , 2023, European journal of cancer.

[25]  Vivek P. Chavda,et al.  Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer , 2022, Cancers.

[26]  J. Kiani,et al.  Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells , 2022, PloS one.

[27]  Kongming Wu,et al.  TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy , 2022, Frontiers in Immunology.

[28]  Sung-Bae Kim,et al.  Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial , 2022, The Lancet.

[29]  Mengke Niu,et al.  Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer , 2022, Journal for ImmunoTherapy of Cancer.

[30]  Kongming Wu,et al.  Increased expression of ECT2 predicts the poor prognosis of breast cancer patients , 2022, Experimental Hematology & Oncology.

[31]  H. Yang,et al.  New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities , 2022, Experimental Hematology & Oncology.

[32]  Yanyong Liu,et al.  Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy , 2022, Experimental Hematology & Oncology.

[33]  R. Pestell,et al.  The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance , 2022, Cancers.

[34]  B. Christensen,et al.  DNA methylation biomarkers for noninvasive detection of triple‐negative breast cancer using liquid biopsy , 2022, International journal of cancer.

[35]  Yuekun Wang,et al.  Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy , 2022, Journal of Hematology & Oncology.

[36]  Changyi Zhang,et al.  The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment , 2022, Journal of Hematology & Oncology.

[37]  Kongming Wu,et al.  Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors , 2022, Journal of Hematology & Oncology.

[38]  Shaojie Jiang,et al.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 , 2022, Journal of Hematology & Oncology.

[39]  H. Rugo,et al.  Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer , 2022, Breast.

[40]  P. Fasching,et al.  Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. , 2022, European journal of cancer.

[41]  Z. Shao,et al.  Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. , 2022, Cell metabolism.

[42]  N. Girard,et al.  Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Jian Zhang,et al.  Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial , 2022, npj Breast Cancer.

[44]  Bo Han,et al.  Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets , 2022, Journal of Hematology & Oncology.

[45]  F. Marmé,et al.  Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. , 2022, Future oncology.

[46]  Yong Rao,et al.  Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer. , 2022, Journal of medicinal chemistry.

[47]  T. Komoto,et al.  Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer , 2022, International journal of molecular sciences.

[48]  R. Béliveau,et al.  The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells , 2022, Pharmaceutics.

[49]  Yongheng Chen,et al.  Recent advances in therapeutic strategies for triple-negative breast cancer , 2022, Journal of Hematology & Oncology.

[50]  A. Bardia,et al.  Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Q. Cheng,et al.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts , 2022, Journal of Hematology & Oncology.

[52]  J. Abraham,et al.  Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends , 2022, Frontiers in Oncology.

[53]  R. Pazdur,et al.  FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  C. Denkert,et al.  Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Jinchao Zhang,et al.  Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. , 2022, Biomaterials.

[56]  Yangqiu Li,et al.  Current insight into the regulation of PD-L1 in cancer , 2022, Experimental Hematology & Oncology.

[57]  B. Shen,et al.  RNA N6-methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer , 2022, Theranostics.

[58]  C. Bakal,et al.  Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition , 2022, Scientific data.

[59]  Liangliang Xu,et al.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors , 2022, Journal of Hematology & Oncology.

[60]  M. Zanoni,et al.  TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer , 2022, Expert opinion on therapeutic targets.

[61]  Aroop Sircar,et al.  Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses , 2022, Journal for ImmunoTherapy of Cancer.

[62]  Jean L Wright,et al.  Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[63]  P. Sidaway.  T-DXd active in HER2-low disease , 2022, Nature Reviews Clinical Oncology.

[64]  Ya Zhang,et al.  Targeting metabolic reprogramming in chronic lymphocytic leukemia , 2022, Experimental Hematology & Oncology.

[65]  H. Bear,et al.  Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer , 2022, Cancer drug resistance.

[66]  Jiang Yin,et al.  Tumor-associated macrophages promote epithelial–mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling , 2022, Cell communication and signaling : CCS.

[67]  Zefei Jiang,et al.  Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification , 2022, Cancer biology & medicine.

[68]  T-DXd: New Standard for HER2-Low Breast Cancer. , 2022, Cancer discovery.

[69]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[70]  Xichun Hu,et al.  Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis , 2022, Journal of Hematology & Oncology.

[71]  A. Grigoriadis,et al.  Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC , 2022, Breast cancer research : BCR.

[72]  Kongming Wu,et al.  Tumor organoids: applications in cancer modeling and potentials in precision medicine , 2022, Journal of Hematology & Oncology.

[73]  Jianyou Shi,et al.  Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment , 2022, Frontiers in Pharmacology.

[74]  Yizhou Jiang,et al.  Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy , 2022, Journal of Hematology & Oncology.

[75]  I. Malami,et al.  Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. , 2022, Epigenomics.

[76]  Howard Y. Chang,et al.  Enhanced safety and efficacy of protease-regulated CAR-T cell receptors , 2022, Cell.

[77]  K. Keyomarsi,et al.  PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers , 2022, Expert opinion on investigational drugs.

[78]  B. Han,et al.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies , 2022, Journal of Hematology & Oncology.

[79]  Xin Hu,et al.  Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial , 2022, Molecular cancer.

[80]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[81]  Kongming Wu,et al.  Notch signaling pathway: architecture, disease, and therapeutics , 2022, Signal Transduction and Targeted Therapy.

[82]  Xiawei Wei,et al.  Cancer vaccines as promising immuno-therapeutics: platforms and current progress , 2022, Journal of Hematology & Oncology.

[83]  Zhong-chao Han,et al.  CAR-NK cells for cancer immunotherapy: from bench to bedside , 2022, Biomarker Research.

[84]  B. Goh,et al.  Clinical translation of patient-derived tumour organoids- bottlenecks and strategies , 2022, Biomarker Research.

[85]  B. Goh,et al.  Clinical translation of patient-derived tumour organoids- bottlenecks and strategies , 2022, Biomarker research.

[86]  M. Kok,et al.  Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer , 2022, Expert opinion on investigational drugs.

[87]  H. Lee,et al.  Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer , 2022, BMC Cancer.

[88]  Kezhen Yi,et al.  Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer , 2022, Molecular cancer.

[89]  P. Fasching,et al.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[90]  C. Francavilla,et al.  Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer , 2022, Open Biology.

[91]  Fan Yang,et al.  Comprehensive metabolomics expands precision medicine for triple-negative breast cancer , 2022, Cell Research.

[92]  Gabor T. Marth,et al.  A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology , 2022, Nature Cancer.

[93]  Kongming Wu,et al.  Combination strategies with PD-1/PD-L1 blockade: current advances and future directions , 2022, Molecular cancer.

[94]  E. Winer,et al.  Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) , 2022, Journal of Clinical Oncology.

[95]  Jin Zhang,et al.  HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk , 2022, Journal of Hematology & Oncology.

[96]  C. Lamb,et al.  New insights in the interaction of FGF/FGFR and steroid receptor signaling in breast cancer. , 2022, Endocrinology.

[97]  Jieqing Li,et al.  Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial , 2022, Therapeutic advances in medical oncology.

[98]  "Very Compelling" Results for ADC in TNBC Trial. , 2021, Cancer discovery.

[99]  R. Greil,et al.  Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  C. Dang,et al.  Targeting cancer metabolism in the era of precision oncology , 2021, Nature reviews. Drug discovery.

[101]  B. Dong,et al.  Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies , 2021, Experimental Hematology & Oncology.

[102]  Jiang Chen,et al.  The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers , 2021, Journal of Hematology & Oncology.

[103]  M. Hou,et al.  FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer , 2021, Biomedicines.

[104]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[105]  E. Jabłońska,et al.  Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells , 2021, International journal of molecular sciences.

[106]  R. Béliveau,et al.  New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells , 2021, Frontiers in Oncology.

[107]  Yoshihiro Matsumoto,et al.  Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade , 2021, Journal of experimental & clinical cancer research : CR.

[108]  P. Fasching,et al.  Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[109]  Zihai Li,et al.  Combination strategies to maximize the benefits of cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[110]  G. Curigliano,et al.  Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development , 2021, Expert opinion on investigational drugs.

[111]  Hao Wu,et al.  Oncolytic viruses for triple negative breast cancer and beyond , 2021, Biomarker Research.

[112]  Kongming Wu,et al.  Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers , 2021, Journal of Hematology & Oncology.

[113]  M. Yamaguchi,et al.  Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells , 2021, Molecular Cancer Therapeutics.

[114]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  Zihai Li,et al.  Novel strategies for immuno-oncology breakthroughs with cell therapy , 2021, Biomarker Research.

[116]  R. Béliveau,et al.  TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer , 2021, Cancer science.

[117]  M. Nodzenski,et al.  Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States , 2021, Cancer.

[118]  X. Guan,et al.  Progress and challenges of immunotherapy in triple-negative breast cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[119]  Kai Zhu,et al.  The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts , 2021, Acta Pharmacologica Sinica.

[120]  Kongming Wu,et al.  Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study , 2021, Biomarker research.

[121]  P. Neven,et al.  Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape , 2021, ESMO open.

[122]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[123]  L. Carey,et al.  Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[124]  Yurou Chu,et al.  Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress , 2021, Journal of Hematology & Oncology.

[125]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[126]  D. Berry,et al.  Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. , 2021, Cancer cell.

[127]  Xing Huang,et al.  Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell , 2021, Journal for ImmunoTherapy of Cancer.

[128]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[129]  M. J. Ramaiah,et al.  Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. , 2021, Life sciences.

[130]  Sung-Bae Kim,et al.  Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  J. Berlin,et al.  Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[132]  Z. Dai,et al.  Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer , 2021, Journal of Hematology & Oncology.

[133]  E. Winer,et al.  Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[134]  G. Ferbeyre,et al.  New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy. , 2021, Trends in cell biology.

[135]  Anping Li,et al.  The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 , 2021, Journal of Hematology & Oncology.

[136]  Anh Nguyen-Duc,et al.  Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.

[137]  G. Kroemer,et al.  Broadening horizons: the role of ferroptosis in cancer , 2021, Nature Reviews Clinical Oncology.

[138]  E. Winer,et al.  Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. , 2021, The Lancet. Oncology.

[139]  S. Basta,et al.  Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy , 2021, Cytokine & Growth Factor Reviews.

[140]  Libing Song,et al.  HOMER3 facilitates growth factor-mediated β-Catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer , 2021, Journal of Hematology & Oncology.

[141]  Y. Nagasaki,et al.  Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles. , 2021, Biomaterials.

[142]  Kai Yang,et al.  Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer , 2021, Theranostics.

[143]  Carlos L. Arteaga,et al.  Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. , 2020, JAMA oncology.

[144]  Xin Hu,et al.  Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer , 2020, Journal of Experimental & Clinical Cancer Research.

[145]  L. Ouyang,et al.  Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy. , 2020, Drug discovery today.

[146]  T. Aas,et al.  Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  D. Hervás,et al.  Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. , 2020, European journal of cancer.

[148]  H. Iwata,et al.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.

[149]  Xiang Song,et al.  Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib , 2020, Frontiers in Oncology.

[150]  Y. Hu,et al.  CAR T-cell therapy for triple-negative breast cancer: Where we are. , 2020, Cancer letters.

[151]  Xin Hu,et al.  Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial , 2020, Cell Research.

[152]  Anping Li,et al.  RDGN-based predictive model for the prognosis of breast cancer , 2020, Experimental Hematology & Oncology.

[153]  Annarita Granaglia,et al.  Pathology of Triple Negative Breast Cancer. , 2020, Seminars in cancer biology.

[154]  P. Buckhaults,et al.  Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer , 2020, Nature Communications.

[155]  Z. Shao,et al.  Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. , 2020, The oncologist.

[156]  N. Xia,et al.  EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo , 2020, Clinical & translational immunology.

[157]  H. Yao,et al.  Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial , 2020, Journal for immunotherapy of cancer.

[158]  J. Behravan,et al.  Single peptides and combination modalities for triple negative breast cancer , 2020, Journal of cellular physiology.

[159]  Y. Bignon,et al.  Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells , 2020, Scientific Reports.

[160]  S. Tolaney,et al.  Role of Immunotherapy in Triple-Negative Breast Cancer. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[161]  A. Bardia,et al.  TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. , 2020, Future oncology.

[162]  R. Hajjo,et al.  Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. , 2020, Current topics in medicinal chemistry.

[163]  L. Qin,et al.  Role of STAT3 signaling pathway in breast cancer , 2020, Cell Communication and Signaling.

[164]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[165]  Zhiwei Hu.  Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer , 2020, Scientific Reports.

[166]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[168]  D. Berry,et al.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.

[169]  K. Hess,et al.  Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  Jiang Liu,et al.  FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1 , 2020, Clinical Cancer Research.

[171]  P. Duchateau,et al.  ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges , 2020, Nature Reviews Drug Discovery.

[172]  A. Bishayee,et al.  Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. , 2019, Seminars in cancer biology.

[173]  Yeon-Hee Park,et al.  Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  P. Fasching,et al.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.

[175]  A. Wolff,et al.  TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer , 2019, Clinical Cancer Research.

[176]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[177]  B. Dong,et al.  Advances and perspectives of PARP inhibitors , 2019, Experimental Hematology & Oncology.

[178]  V. Jain,et al.  PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. , 2019, Drug discovery today.

[179]  Kongming Wu,et al.  Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor , 2019, OncoTargets and therapy.

[180]  C. Bailly.  Irinotecan: 25 years of cancer treatment. , 2019, Pharmacological research.

[181]  R. Salgia,et al.  Notch Signaling in Breast Cancer: From Pathway Analysis to Therapy. , 2019, Cancer letters.

[182]  Jack Junjie Chan,et al.  Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond , 2019, Therapeutic advances in medical oncology.

[183]  Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment , 2019, Case Medical Research.

[184]  D. Generali,et al.  Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells , 2019, Scientific Reports.

[185]  Z. Zeng,et al.  Neoantigen vaccine: an emerging tumor immunotherapy , 2019, Molecular Cancer.

[186]  P. Nuciforo,et al.  FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[187]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[188]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[189]  M. V. Giuli,et al.  Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype , 2019, Journal of oncology.

[190]  Yaping Wang,et al.  Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. , 2019, Pathology, research and practice.

[191]  N. Turner,et al.  Targeting the PI3-kinase pathway in triple negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[192]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[193]  Sung-Bae Kim,et al.  Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study , 2019, Journal of global oncology.

[194]  Li Yan,et al.  STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review , 2019, Journal of Experimental & Clinical Cancer Research.

[195]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[196]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[197]  E. Winer,et al.  Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[198]  S. Loi,et al.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[199]  S. Ramaswamy,et al.  Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models , 2019, Scientific Reports.

[200]  K. Polyak,et al.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. , 2019, Cancer discovery.

[201]  Wei Li,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[202]  M. Rezai,et al.  Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[203]  Fang Yang,et al.  Androgen blockade based clinical trials landscape in triple negative breast cancer. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[204]  Kongming Wu,et al.  Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine , 2018, Experimental Hematology & Oncology.

[205]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[206]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[207]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[208]  P. Elvin,et al.  Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response , 2018, Molecular Cancer Therapeutics.

[209]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[210]  A. Font,et al.  Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss , 2018, Clinical Cancer Research.

[211]  Ping Zhang,et al.  TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. , 2018, Biochemical and biophysical research communications.

[212]  F. Puglisi,et al.  Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. , 2018, Cancer treatment reviews.

[213]  Lili Wang,et al.  Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide , 2018, Oncogene.

[214]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[215]  D. Generali,et al.  The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells , 2018, Journal of experimental & clinical cancer research : CR.

[216]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[217]  Peter Schmid,et al.  Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  P. Hegde,et al.  Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. , 2017, Seminars in cancer biology.

[219]  S. Loi,et al.  Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. , 2017, Cancer research.

[220]  J. Barrett,et al.  A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers , 2017, Clinical Cancer Research.

[221]  L. Orlando,et al.  Targeting triple negative breast cancer with histone deacetylase inhibitors , 2017, Expert opinion on investigational drugs.

[222]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[223]  A. Ravaud,et al.  Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. , 2017, European urology.

[224]  Pradip De,et al.  PI3K‐AKT‐mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials , 2017, Pharmacology & therapeutics.

[225]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[226]  C. Bakal,et al.  Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer , 2017, Clinical Cancer Research.

[227]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[228]  N. Turner,et al.  Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.

[229]  G. Lozano,et al.  TNBC invasion: downstream of STAT3 , 2017, Oncotarget.

[230]  F. Bertucci,et al.  Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[231]  A. Schneeweiss,et al.  Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[232]  A. Guerrero-Zotano,et al.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment , 2016, Cancer and Metastasis Reviews.

[233]  J. Xu,et al.  The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer , 2016, International journal of biological sciences.

[234]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[235]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[236]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[237]  J. Sicklick,et al.  Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma , 2016, Molecular Cancer Therapeutics.

[238]  P. Lin,et al.  Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model , 2016, Molecular Cancer.

[239]  Sue Chua,et al.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.

[240]  Mingjian Ding,et al.  Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer. , 2016, Oncology letters.

[241]  J. Grenier,et al.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[242]  E. Perez,et al.  Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. , 2016, Clinical breast cancer.

[243]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[244]  Xin Hu,et al.  Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer , 2016, Breast Cancer Research.

[245]  Shiying Yu,et al.  Notch signaling: an emerging therapeutic target for cancer treatment. , 2015, Cancer letters.

[246]  Sriganesh Srihari,et al.  Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.

[247]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[248]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[249]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[250]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[251]  R. Nahta,et al.  Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC) , 2015, Vaccines.

[252]  Shiying Yu,et al.  Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis , 2015, PloS one.

[253]  Hua Wu,et al.  Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis , 2015, Scientific Reports.

[254]  C. Caldas,et al.  PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[255]  P. Tan,et al.  Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[256]  Jianguang Wang,et al.  Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT–mTOR pathway , 2015, Anti-cancer drugs.

[257]  Fabrice André,et al.  Rationale for targeting fibroblast growth factor receptor signaling in breast cancer , 2015, Breast Cancer Research and Treatment.

[258]  D. Durden,et al.  Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma , 2015, Cancer Chemotherapy and Pharmacology.

[259]  D. Durden,et al.  Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model , 2014, Cancer Cell International.

[260]  S. Hilsenbeck,et al.  STAT3 Signaling Is Activated Preferentially in Tumor‐Initiating Cells in Claudin‐Low Models of Human Breast Cancer , 2014, Stem cells.

[261]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[262]  M. Rezai,et al.  Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44) , 2014, Annals of Surgical Oncology.

[263]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[264]  H. Lee,et al.  Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets , 2014, Annals of Surgical Oncology.

[265]  J. Reis-Filho,et al.  Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[266]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[267]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[268]  L. Miele,et al.  Notch inhibitors for cancer treatment. , 2013, Pharmacology & therapeutics.

[269]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  Thomas Bachelot,et al.  Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.

[271]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[272]  M. Duffy,et al.  Targeted therapy for triple‐negative breast cancer: Where are we? , 2012, International journal of cancer.

[273]  D. V. Von Hoff,et al.  Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. , 2012, European journal of cancer.

[274]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[275]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[276]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  A. Rangarajan,et al.  A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells , 2011, Molecular Cancer Therapeutics.

[278]  S. Eccles.  The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. , 2011, The International journal of developmental biology.

[279]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[280]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[281]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[282]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[283]  L. Liaw,et al.  Tumorigenesis and Neoplastic Progression Notch2 Signaling Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth , 2007 .

[284]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[285]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[286]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[287]  K. M. Nicholson,et al.  LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. , 2003, Cancer letters.

[288]  L. Hennighausen,et al.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. , 2002, Development.

[289]  W. Hahn,et al.  Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells , 2002, Nature Medicine.

[290]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[291]  P. Fisher,et al.  EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells. , 2020, Advances in cancer research.

[292]  L. Dušek,et al.  EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. , 2015, Ceskoslovenska patologie.

[293]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[294]  T. Kume.  Ligand-dependent Notch signaling in vascular formation. , 2012, Advances in experimental medicine and biology.

[295]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[296]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.

[297]  R. Nahta,et al.  Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer ( EC ) and HER-1 and IGF-1 R in Triple-Negative Breast Cancer ( TNBC ) , 2022 .